



August 14, 2025

Kusurinomadoguchi, Inc.

Kouji Tsutsumi, President and Representative Director

(TSE Growth:5592)

Transcript of Financial Results Briefing for the First Quarter of Fiscal Year Ending March 31, 2026

1. Notes on Transcript

This transcript, including earnings forecasts, has been prepared based on the accuracy of the information available to the Company at the time of publication and certain assumptions that the Company deems reasonable, and actual results may differ due to various risks and uncertainties, such as changes in economic conditions, changes in customer needs, and changes in laws and regulations, and we do not promise to achieve them.

This documentation has been prepared in the Japanese with the English translation. In the event that there arise any doubts or controversies between Japanese and English expression, the Japanese version shall prevail.

<https://youtu.be/swFhwyYPAes>

※YouTube video in Japanese only

2. Definition

Shot Sales : Sales earned as initial cost income when various services are introduced

Gross “Shot” Profit : "Shot Sales" minus costs related to such sales

Stock Sales : Defined as sales that can be earned continuously in the future based on a monthly subscription fee or contract

Gross “Stock” Profit : “Stock Sales” minus the cost of maintaining and providing the service.

3. Transcript of Financial Results Briefing for the First Quarter of Fiscal Year Ending March 31,2026



2025年8月14日

2026年3月期第1四半期
決算説明資料

株式会社くすりの窓口 証券コード：5592

くすりの窓口 | ©kusurinomadoguchi, inc. All Right Reserved.

This is Tsutsumi from Kusurinomadoguchi,Inc.
Thank you for viewing.
Now, I would like to present the financial results for the first quarter of fiscal year ending March 2026.
First, let me present the consolidated financial overview.

1. 2026年3月期第1四半期 連結決算概要
2026年3月期第1四半期 連結決算概要

2026年3月期 第1四半期	全事業の売上高が前期を上回ったため、増収増益。	連結売上高 29.1億円 前期比 +11%	連結営業利益 6.2億円 前期比 +65%	ストック粗利 8.5億円 前期比 +23%
メディア事業	施設保有数の増加に加え、処方箋ネット受付数も増加し、前期比で増収増益。	売上高 11.5億円 前期比 +9%	ストック粗利 3.8億円 前期比 +42%	
みんなのお薬箱事業	不動産在庫サービスは、中堅・大手の取引量の増加により、増収増益。仕入れサポートサービスは改善途中だが、流通額は徐々に回復傾向。	売上高 8.7億円 前期比 +12%	ストック粗利 3.8億円 前期比 +15%	
基幹システム事業	調剤薬局向けレセコン、薬歴と調剤監査システムの導入が進み増収。新商材のリリースなど先行投資の影響によりストック粗利は減益。	売上高 8.2億円 前期比 +11%	ストック粗利 1.4億円 前期比 △9%	

※当社は単一セグメントのため各事業の売上とストック粗利を重要指数としております。

くすりの窓口 | ©kusurinomadoguchi, inc. All Right Reserved.

4

Regarding consolidated net sales and consolidated operating profit, we achieved increased revenue and profit as sales from all businesses exceeded the previous period.

Consolidated net sales reached 2.91 billion yen, an 11% increase compared to the previous period, and consolidated operating profit landed at 620 million yen, a 65% increase.

Given that our company operates as a single segment, we measure growth indicators based on stock sales and gross stock profit of each business rather than consolidated operating profit.

For the Media business, in addition to an increase in the number of facilities with online prescription reception services, the number of online prescription receptions also steadily increased, resulting in increased revenue and profit compared to the previous period.


For the Everyone's Medicine Box Business, we achieved increased revenue and profit due to increased transaction volume from mid-sized and large companies using our B2B marketplace of inactive medication inventory. The purchasing support service is still in the process of improvement, but GMV is gradually showing a recovery trend.

For the Core System business, revenue increased due to the progress in introducing receipt computer systems, electronic medication history data, and dispensing audit system for dispensing pharmacies. On the other hand, gross stock profit decreased due to the impact of upfront investments such as the release of new products.

2. 2026年3月期第1四半期 業績報告

連結売上高

2025年3月期は診療・調剤報酬改定の年度で特需があり業績も大きく伸長しましたが、2026年3月期第1四半期のショット売上、ストック売上は共にその前年を上回りました。2026年3月期第1四半期のストック売上は、3事業が全て前期および前四半期で増収となったことで過去最高を更新しました。



くすりの窓口 | ©kusurinomadoguchi, inc. All Right Reserved.

6

Next, let me show the quarterly sales trends.

Fiscal year ended March 2025 was a year of revision of medical and dispensing fees, which created special demand and significantly boosted performance. However, both shot sales and stock sales for the first quarter of fiscal year ending March 2026 exceeded the previous period.


In particular, stock sales for the first quarter of fiscal year ending March 2026 reached a record high as all three

businesses achieved increased revenue compared to both the same period last year and the previous quarter.

2. 2026年3月期第1四半期 業績報告

連結ストック粗利

2026年3月期第1四半期は、メディア事業とみんなのお薬箱事業のストック売上が増加したことによりストック粗利は過去最高を更新しました。みんなのお薬箱事業は、中堅・大手による不在在庫サービスの取引量の増加により好調でした。



Next is consolidated gross stock profit.


Consolidated gross stock profit reached a record high due to increased stock sales in the Media business and Everyone's Medicine Box business.

The Everyone's Medicine Box business performed well due to increased transaction volume of B2B marketplace of inactive medication inventory by mid-sized and large companies.

2. 2026年3月期第1四半期 業績報告

連結営業利益

連結営業利益は、全ての事業が増収だったことと、子会社の合理化をはじめとするグループ全体のコスト適正化に努めたこととで、過去最高を更新しました。




Next is consolidated operating profit.

Consolidated operating profit reached a record high due to increased revenue across all businesses and our efforts to optimize costs throughout the group, including rationalization of subsidiaries.

2. 2026年3月期第1四半期 業績報告

連結販管費と従業員数

子会社のコストの適正化が進み、販管費、稼働人数ともに前期比で減少いたしました。



Next are consolidated SG&A expenses and employee count.

Through the rationalization of subsidiaries that we have been working on since the previous period, cost optimization of subsidiaries is steadily progressing.

The number of employees also increased slightly.

We will continue to optimize costs and personnel going forward.

連結損益計算書

親会社株主に帰属する四半期純利益は、2026年3月期の業績予想に対して進捗が遅れておりますが、予定している第2四半期の資本金の減資に伴う繰越欠損金に係る繰延税金資産の追加計上で計画通りに推移する見通しです。

単位：百万円	2026年3月期 第1四半期	2025年3月期 第1四半期	増減率	2025年3月期 第4四半期	増減率
売上高	2,914	2,629	+11%	2,778	+5%
売上総利益	1,688	1,542	+10%	1,472	+15%
営業利益	629	382	+65%	397	+58%
経常利益	645	379	+70%	402	+60%
親会社株主に帰属する 四半期純利益	386	239	+61%	472	△18%
EBITDA	975	669	+46%	714	+37%

This is the consolidated income statement.

As indicated, while the quarterly net profit attributable to shareholders of the parent company is behind schedule compared to the fiscal year ending March 2026 performance forecast, we expect it to progress as planned with the additional recording of deferred tax assets related to tax loss carryforwards associated with the planned capital reduction in the second quarter.

2026年3月期第1四半期の繰越欠損金の処理について


6月24日の第21期定時株主総会においては、第2号議案「資本金の額の減少の件」のご承認いただき、減資の手続きを進めており、資本金の額の減少の効力発生日が9月を予定しております。

この資本金の減少に伴う繰越欠損金に係る繰延税金資産の追加計上は第2四半期に予定されており、第1四半期の「親会社株主に帰属する四半期純利益」の進捗率は遅れではないため、通期の業績予想につきましては変更ございません。

計上金額につきましては、会計監査人や顧問税理士へも確認を取り、第2四半期の決算発表時に開示致します。

Next is about the treatment of tax loss carryforwards for the first quarter of fiscal year ending March 2026. As I briefly explained earlier, it is as indicated.

2026年3月期第1四半期の業績進捗率



Next is the performance progress rate for the first quarter of fiscal year ending March 2026.

The progress rate is as indicated, but we recognize that we are progressing almost according to plan.

連結貸借対照表


仕入れサポートサービスの請求回収代行スキームが変更になったことで、現預金と流動負債が大幅に減少いたしました。また、第1四半期に配当金と税金の支払を行っております。

単位：百万円	2026年3月期 第1四半期	2025年3月期 第1四半期	増減率	2025年3月期 第4四半期	増減率
総資産	11,874	18,888	△37%	12,157	△2%
流動資産	5,879	13,977	△58%	6,229	△6%
現預金	1,888	10,250	△82%	2,104	△10%
固定資産	5,995	4,911	+22%	5,928	+1%
負債	3,249	12,242	△74%	3,640	△11%
流動負債	2,772	11,545	△76%	3,125	△11%
固定負債	477	697	△32%	515	△7%
純資産	8,625	6,645	+30%	8,516	+1%

Next is the balance sheet, which is also as indicated.

3. 事業内容と業績

メディア事業 | ビジネスモデル



15

From here, I will explain each business.

First, let me discuss the Media Business.

Regarding this business model, the major revenue source for recurring sales comes from online prescription reception fees from EPARK Kusurinomadoguchi, which is one of Japan's largest media platforms for dispensing pharmacies, and EPARK Medication Notebook App, which is similarly one of Japan's largest medication notebook apps.

Additionally, recurring sales include monthly listing fees for Rich Plans that provide top site positioning, and system fees for Pharmacy Support, which is a customer repeat promotion system.

For shot sales, the main revenue sources are initial implementation costs for Rich Plans and Pharmacy Support.

3. 事業内容と業績

メディア事業 | 売上高

ショット売上は、前期の水準(四半期平均332百万円)で推移しており、ストック売上は、処方箋ネット受付数の増加により売上が伸長しております。

※メディア事業にEPARK人間ドックの売上を含めておりましたが、今後未病予防事業として報告するため、遡って売上を修正しております。



くすりの窓口 | ©kusurinomadoguchi, inc. All Right Reserved.

16

Here are the sales figures for the Media Business.

First quarter shot sales landed at 332 million yen, which is the quarterly average level of the previous period's shot sales.


Stock sales progressed steadily due to an increase in the number of facilities offering online prescription reception services, as well as an increase in the number of online prescription receptions.

3. 事業内容と業績

メディア事業 | ストック粗利

処方箋ネット受付数の増加と粗利率の改善により増益となりました。2025年3月期第1四半期の粗利率は39%、2026年3月期の第1四半期の粗利率は47%となり、過去最高を更新しました。2025年3月期第4四半期は、将来に向けての先行投資などを行ったことでストック粗利が減少しておりました。

※メディア事業にEPARK人間ドックの売上を含めておりましたが、今後未病予防事業として報告するため、遡ってストック粗利を修正しております。



※一部の予約定義の修正を2025/3の1Qと2Qで調整しております。

くすりの窓口 | ©kusurinomadoguchi, inc. All Right Reserved.

17

Next is gross stock profit.

Profits increased due to the growth in online prescription receptions and improved gross stock profit margins.



The gross stock profit margin for Q1 of fiscal year ended March 2025 was 39%, and for Q1 of fiscal year ending March 2026, it was 47%.

Additionally, the quarterly gross stock profit for the Media Business reached a record high.

3. 事業内容と業績

メディア事業 | KPI（重要指数）

EPARKお薬手帳アプリも累計ダウンロード数が600万を突破後も好調に推移。EPARKくすりの窓口からお薬手帳への囲い込みが進んでおります。



*1. 調剤医療費総額、処方箋枚数(受付回数)令和4年4月～令和5年3月
*2. 1予約当たりの処方箋枚数を1.2枚で計算
*3. *1を元に当社実績割合で算出

These are the KPIs for the Media Business.

Online prescription receptions increased by 226,000 cases compared to Q1 of fiscal year ended March 2025. Accordingly, stock sales are steadily accumulating.

The total number of downloads for EPARK Medication Notebook App downloads reached 6.43 million. We will continue to enhance functions that add value to the medication notebook app to increase downloads.

The number of contracted facilities is also growing steadily, reaching 23,089 stores.

Regarding the market share of online prescription reception services, while we maintain the No.1 position in Japan, service recognition remains a challenge, and our market share is still low at just under 2%. However, from another perspective, this indicates extremely high market potential.

Going forward, we will implement various measures to further expand our online prescription reception services.

処方箋ネット受付周りの施策

処方箋ネット受付の機会損失を防ぐ施策

患者様がネット予約した薬局店舗に薬の在庫がない場合の解決策である『AI stock 機能』。キャンセルデータと薬の在庫データをもとに自社グループの予約患者様の離脱抑止や商圈内のキャンセル予約にアプローチが出来ることから、特に大手の調剤薬局やドラッグストアからの引き合いが強く、**2026年3月期第1四半期で1,089店舗を獲得。**



リアル店舗の強化施策

店舗での業務効率化施策

・AI受付

調剤薬局の人員費高騰や薬剤師不足の課題に対する施策として店舗内の基本受付業務をAIが自動化するシステムは、**大手ドラッグでの導入が進んでいます。**

・その他

- ◇処方箋受付機
- ◇お薬の受取りロッカー
- ◇発券機



Next are the topics for the Media Business.

Regarding AI Stock, this service prevents opportunity losses from medication shortages at stores, enabling pharmacies to dispense medications for more patients and subsequently retain customers. As this is a unique service not offered by competitors, it has strong demand.


In Q1 of fiscal year ending March 2026, we acquired 1,089 stores.

We are also focusing on products and services related to reception operations at physical stores.

AI Reception, which handles basic reception duties at stores, is being increasingly adopted by major drugstore chains. Other offerings include prescription reception machines that allow tower mansion residents to receive online medication guidance and pick up dispensed medications without visiting the pharmacy, medication pickup lockers, and ticket dispensing machines for patients visiting stores to wait for medication pickup. We are enhancing products and services that reduce store operational burden and staffing requirements.

3. 事業内容と業績

みんなのお薬箱事業 | ビジネスモデル



Next is the Everyone's Medicine Box business.

This business model's main revenue sources are the purchasing support service, where we receive a portion of the price as commission by supporting the procurement-related aspects of dispensing pharmacies and medical institutions, and the monthly usage fees for the AI-powered inventory management system(e-order), which are basically introduced simultaneously.


Additionally, commission fees from B2B marketplace of inactive medication inventory, which matches dispensing pharmacies that want to sell unused medicines with dispensing pharmacies and medical institutions that want to buy pharmaceuticals at low prices online and collect fees from both parties, also constitute components of stock profit.

Furthermore, regarding shot sales, the main revenue source is the initial setup costs when introducing the e-order system.

3. 事業内容と業績

みんなのお薬箱事業 | 売上高

ストック売上高は、不動産在庫サービスの中堅・大手の取引量の増加により大きく伸長し、過去最高を更新しました。
仕入れサポートサービスは改善途中ですが、一旦撤退した大手の顧客も徐々に戻ってきており、流通額も徐々に回復傾向です。



22

Next are the sales of Everyone's Medicine Box Business.


Stock sales grew significantly due to increased transaction volume from mid-sized and large companies in the B2B marketplace of inactive medication inventory services, reaching a record high.

For the purchasing support service, adjustments with pharmaceutical wholesalers were completed in the previous period, and operations normalized from this period. While purchasing support service is still in the process of improvement, major clients who had temporarily withdrawn are gradually returning, and GMV is also showing a gradual recovery trend.

3. 事業内容と業績

みんなのお薬箱事業 | ストック粗利

ストック売上が好調だったこともあり、四半期のストック粗利としては、過去最高益を更新いたしました。



くすりの窓口 | ©kusurinomadoguchi, inc. All Right Reserved.


23

Next is the gross stock profit of the Everyone's Medicine Box Business.


Gross stock profit achieved a record high for quarterly gross stock profit, partly due to strong stock sales performance.

3. 事業内容と業績

みんなのお薬箱事業 | KPI (重要指標) ※仕入れサポートサービス+不動産在庫サービス



くすりの窓口 | ©kusurinomadoguchi, inc. All Right Reserved.



*1.厚労省「薬局業別業に關する基礎資料(概況)」より
*2.厚労省「医療施設動態調査(令和3年1月末掲載)」より
*3.IGVIA医薬品市場統計公表上データ (期間:2022年4月~2023年3月)

24

These are the KPIs for the Everyone's Medicine Box Business.

Regarding GMV (Gross Merchandise Value), there was a decrease in GMV in fiscal year 2025 due to the departure of some major clients from the purchasing support service, but some of these major clients have begun resuming transactions.

The number of contracted facilities increased by 2,127 facilities from the first quarter of fiscal year 2025. The main factor for this increase was the contribution from the increased number of contracted facilities by the B2B marketplace of inactive medication inventory.

3. 事業内容と業績

みんなのお薬箱事業 | トピックス

不動産在庫サービスの拡大

不動産在庫サービスについては、キャンペーン等による営業施策により、中堅・大手の導入が進み、不動産在庫サービスの流通額とそれに伴う手数料が増加いたしました。引き続き既存顧客の囲い込みと新規獲得により、2026年3月期は拡大して参ります。

みんなくす電気

全国の医療・薬局・介護施設法人様の現在の電気のご利用状況に応じて、今までと変わらない品質のまま、電気料金を削減する最適なプランを提案しております。




Next are the topics.

Regarding the B2B marketplace of inactive medication inventory, campaign deployment increased GMV from mid-sized and large companies and the accompanying commission fees. We will continue to expand in fiscal year 2026 through retention of existing customers and acquisition of new ones.

Everyone's Medicine Box Electricity provides three plans that reduce electricity costs while maintaining the same quality as before, based on the current electricity usage of medical, pharmacy, and nursing care facility corporations nationwide. It continues to perform steadily as it leads to cost reduction.

3. 事業内容と業績

基幹システム事業 | ビジネスモデル



Next, regarding the core system business.

For core systems, we have a comprehensive lineup of core systems for each field: for pharmacies, we offer receipt computer systems, medication history data, and dispensing audit systems; for nursing care, we provide receipt computer systems, record systems, and bed sensors; and for hospitals and clinics, we offer billing systems, reception systems, electronic medical records, AI telephone reception, etc. We have established a system that enables sales in each of these areas.

Our business model involves receiving monthly software usage fees, which constitute our stock sales.

On the other hand, costs incurred when building system environments, such as replacing computers during system implementation, become shot sales.


3. 事業内容と業績

基幹システム事業 | 売上高

電子薬歴やレセコン、調剤監査システムの導入が進み前期比でショット売上が増加いたしました。

2025年3月期第4半期に電子カルテの大型案件を計上しており、前四半期よりショット売上は減少しております。

ストック売上は、着実に積み上がり過去最高を更新しました。



This is the sales for the core system business.

Shot sales for core systems increased compared to the previous period due to progress in implementing electronic medication history data, receipt computers, and dispensing audit systems. We had 46 dispensing audit systems installed. We plan to continue expanding sales going forward.


Shot sales decreased compared to the previous quarter due to the recording of a large electronic medical record project in the fourth quarter of fiscal year ended March 2025.

Stock sales has steadily accumulated each quarter, reaching record highs.

3. 事業内容と業績

基幹システム事業 | ストック粗利

新商材への開発投資によりストック原価が増加したことでストック粗利が減益となりました。




29

This is the gross stock profit for the core system business.

Regarding gross stock profit, it decreased due to an increase in depreciation expenses of software that was capitalized as an asset due to development investments in new products.

3. 事業内容と業績

基幹システム事業 | KPI (重要指数) 業種別施設保有数推移 (四半期)



30

These are the KPIs for core systems.

The number of contracted facilities with core systems increased by 423 facilities compared to fiscal year ended March 2025, reaching 8,100 facilities.

We aim to create added value by strengthening integration between core system business systems and data accumulated from other businesses and achieve breakthroughs of 10,000 contracted facilities at an early stage.


3. 事業内容と業績

基幹システム事業 | トピックス

Cube.i (キューブ・アイ)

調剤過誤 (薬剤の取り違い、数量間違い)を未然に防ぐシステム

Cube.i (キューブ・アイ) は、お薬を輪ゴムで留めたまま監査台に乗せるだけで、医薬品と錠数の監査が完了する調剤監査システム
レセプトコンピュータから処方情報を取得し、1薬品毎に画像と錠数の重さをチェック。薬剤違い、数量違いなどが見付かった場合はエラーが表示され調剤過誤を未然に防ぎます。



These are the topics for core systems.


Cube.i is a system that prevents medication mix-ups and quantity errors in pharmacists' dispensing operations.

Its features include the ability to simultaneously audit both medication types and quantities within the conventional picking workflow, with a judgment time of just one second. Subsequent double-checking by pharmacists prevents dispensing errors.

There is strong interest from major drugstore chains and others, and we delivered 46 units in the first quarter.

3. 事業内容と業績

未病予防事業 | ビジネスモデル



Next, we will introduce the pre-disease prevention business, which will be newly disclosed from the fiscal year ending March 2026.

Pre-disease prevention refers to initiatives that improve health conditions before the onset of illness and prevent the development of diseases.

In addition to EPARK Complete Medical Checkup, which has been providing optional health screenings reservations, our company has expanded into Kusurinomadoguchi Health Screenings support, a reservation agency service for mandatory health screenings, and Specific Health Guidance that provides professional guidance to selected members based on health screenings results to prevent the onset and progression of lifestyle-related diseases.

Stock sales consist of Kusurinomadoguchi Health Screenings Support and EPARK Complete Medical Checkup. Kusurinomadoguchi Health Screenings Support is a service where we receive a per-person commission from health insurance associations when their members complete health screenings. EPARK Complete Medical Checkup operates on a business model where we receive commissions for selected courses when users who make direct online reservations and pay out-of-pocket actually complete their chosen complete medical checkup courses.

Shot sales come from Specific Health Guidance.

Specific Health Guidance is a service where we receive commissions from health insurance associations at the time of initial consultation and completion.

The number of reservations shown as a KPI represents the total number of reservations from both Kusurinomadoguchi Health Screenings Support and EPARK complete Medical Checkup. There was significant growth in the first quarter of fiscal year ending March 2026.

This was due to acquiring a major corporate health insurance association, which led to an increase in reservations from their members.

Sales are recorded in the month when these reservation holders actually undergo health screenings or complete medical checkups. Since it typically takes 2-3 months from reservation to sales recognition, this will impact performance from the second quarter onwards.

4. 2026年3月期 業績見通し

2026年3月期 業績見通し

単位：百万円	2022年3月期	2023年3月期	2024年3月期	2025年3月期	2026年3月期	前期比
売上高	6,489	7,420	8,721	11,199	12,300	+10%
売上原価	3,117	3,346	3,788	4,724	-	-
売上総利益	3,372	4,074	4,932	6,475	-	-
販売管理費	2,657	3,024	3,562	4,521	-	-
営業利益	715	1,050	1,370	1,953	2,200	+12%
経常利益	815	938	1,325	1,940	2,135	+10%
親会社株主に帰属する当期純利益	515	391	870	2,034	2,240	+10%

Next, I will present our business outlook for the fiscal year ending March 2026.

In the fiscal year ended March 2025, the new features of the electronic prescription management service from our subsidiary MOINET SYSTEM, CO., which was subject to special demand due to subsidy grants, made a significant contribution to our performance.


For the fiscal year ending March 2026, while we do not expect such special demand, we aim for double-digit growth in both sales and operating profit and plan an annual dividend of 30 yen.

There are no revisions to our performance forecast for this first quarter. We will continue to develop our business to achieve our plans.

5. 中期経営計画

中期経営計画

ストック売上を積み上げながら安定的な利益を確保し、**ストック売上200億円、営業利益50億円以上を目指します。**



Next, regarding our medium-term management plan.


Similar to our performance forecast for the fiscal year ending March 2026, there are no changes here either.

For the fiscal year ending March 2030, we target stock sales of 20 billion yen and consolidated operating profit of 5 billion yen or more.

5. 中期経営計画

顧客基盤の拡大

2030年3月期末までに10万施設を目指します。



38

Finally, regarding the expansion of our customer base.

Since the plan announcement, we continue to aim for acquiring 100,000 facilities by the fiscal year ending March 2030.



ヘルスケア領域に新しい価値を提供し、
事業を通じて「社会課題の解決」に貢献する

くすりの窓口グループをご支援賜りますようお願い申し上げます

"To provide new value to the healthcare sector and contribute to solving social issues through our business" - we will work toward this mission.

We ask for your continued support.

This concludes my presentation. Thank you very much.

注意事項

当社の連結決算は日本会計基準を採用しています。

業績予想などを含む本資料は、当社が現時点で入手可能な情報の正確性と、合理的であると判断する一定の前提に基づいて作成しており、実際の業績は、経済状況の変化や顧客ニーズの変化、または法規制等の変更等、さまざまなリスクや不確定な要因により異なる可能性があります、その達成を約束するものではありません。

IRに関するお問い合わせ

株式会社くすりの窓口 管理本部IR担当

E_mail

ir@kusurinomadoguchi.co.jp

IR サイト

<https://kusurinomadoguchi.co.jp/ir/>